Fig. 2
Pretreatment with LXA4 or LXB4 reduces astrocyte and Müller cell reactivity in the inner retina. A Schematic of intravitreal pretreatment and subsequent LPS retinal inflammation assessment at 48 h. B Representative images showing pretreatment with LXA4 or LXB4 strongly reduced GFAP-positive Müller glia fibers in the inner retina (GFAP, arrows). C Pretreatment with LXA4 or LXB4 did not appear to reduce LPS-induced activated microglia (amoeboid Iba1; green, arrows) compared to vehicle control (Veh). D Treatment with LXA4 or LXB4 did not appear to alter the levels of infiltrating macrophages (F4-80: green) at the vitreo-retinal interface (arrows). E Corresponding quantification of activated Müller glia in the inner retina expressed as the number of GFAP + processes. LXA4 and LXB4 pretreatment significantly reduced LPS-activated Müller glia compared with vehicle (Veh, *p < 0.05, **p < 0.01). F Quantification of activated (amoeboid) microglia from the inner retina showed no significant reduction with LXA4 or LXB4 pretreatment compared to vehicle (Veh). G Infiltrating macrophages were quantified at the vitreo-retinal interface, showing no significant effect of LXA4 and LXB4 treatment. (GCL; ganglion cell layer, IPL; inner plexiform layer, INL; inner nuclear layer, scale bars represent 100 µm, graph bars represent SE)